US Stock Insider Trading | uniQure disclosed two insider transactions on February 27

2026-04-03 15:18:48

On February 27, 2026, uniQure (QURE) disclosed two insider transactions involving company insiders. Director Kapusta Matthew C sold 12.4k shares on February 25, 2026.

[Recent Insider Trading]

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/US$	Total amount/US$
February 27, 2026	Executive	KLEMT CHRISTIAN	February 25, 2026	Sold	6217	23.86	148.3k
February 27, 2026	Director	Kapusta Matthew C	February 25, 2026	Sold	12.4k	23.86	295.3k
January 14, 2026	Director	Gut Robert	January 12, 2026	Sold	500	25.03	12.5k
January 14, 2026	Director	Gut Robert	January 12, 2026	Bought	17.8k	14.08	250.8k
January 14, 2026	Director	Gut Robert	January 12, 2026	Sold	7803	25.09	195.8k
January 14, 2026	Director	Gut Robert	January 12, 2026	Sold	17.3k	24.39	422.2k
January 12, 2026	Director	Kaye Jack	January 9, 2026	Bought	6390	19.39	123.9k
January 12, 2026	Director	Kaye Jack	January 9, 2026	Sold	6390	27.28	174.3k
November 10, 2025	Director	Gut Robert	November 6, 2025	Bought	15.8k	4.57	72.4k
November 10, 2025	Director	Gut Robert	November 6, 2025	Sold	15.8k	27.22	431.2k

[Company Profile]

uniQure N.V. was established as a private limited liability company on January 9, 2012, in accordance with relevant Dutch legal provisions. The company is a biotechnology firm specializing in gene therapy, dedicated to developing a single treatment approach for patients with rare diseases and severe illnesses. Its pipeline includes clinical candidate drugs for Huntington’s disease, amyotrophic lateral sclerosis associated with SOD1 mutations, intractable medial temporal lobe epilepsy, and Fabry disease, reflecting its focus on advancing innovative therapies in the gene therapy field.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.